Targacept, Inc. , a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plan
Read the original:
Targacept Announces Decision by AstraZeneca to Advance AZD1446 in Alzheimer’s Disease
ExonHit Therapeutics hopes to commercialize a microarray-based clinical test for diagnosing Alzheimer’s disease in Europe by the first quarter of next year, the company said this week.
More:
ExonHit Preps Affy-Based Alzheimer’s Test for 2011 Launch (GenomeWeb News)
Transition Therapeutics Inc. fell the most since 2002 after the company and partner Elan Corp. said nine people died in a mid-stage clinical trial of a drug being developed to treat Alzheimer’s diseas…
Read this article:
Transition falls after ... continue reading